<DOC>
	<DOCNO>NCT01840592</DOCNO>
	<brief_summary>The purpose study find effect , good and/or bad , combination drug sorafenib combination drug doxorubicin might growth spread liver cancer ( HCC ) .</brief_summary>
	<brief_title>Sorafenib Plus Doxorubicin Patients With Advanced Hepatocellular Carcinoma With Disease Progression Sorafenib</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Diagnosis HCC confirm histologically , exclude mixed HCC histology ( e.g . HCC plus cholangiocarcinoma ) fibrolamellar variant . Prior treatment sorafenib single agent combination , less 200 mg every day dose sorafenib , radiologic evidence progression disease . Measurable disease use RECIST 1.1 criterion . Noncirrhotic ChildPugh A cirrhosis . Expected survival least 3 month . Age ≥ 18 year . KPS ≥ 70 % Fully recover prior surgery and/or radiation none within 2 week initiate treatment . Patients may treat locoregional liver direct therapy embolization , chemoembolization include drugeluting bead doxorubicin chemoembolization ( prior non drug elute bead chemoembolization doxorubicin exclude ) , radiation , radioactive microspheres , etc. , provide either target lesion subject local therapy and/or target lesion ( ) within field local therapy show increase ≥25 % size since last treatment . Such therapy must complete least 4 week prior treatment initiation . Patients receive palliative radiation therapy bone need wait 4 week begin protocol therapy . Informed consent must obtain prior study initiation . Total bilirubin ≤3.0 mg/dL evidence bile obstruction . Absolute neutrophil count ( ANC ) ≥1,500/μL . Platelets ≥75,000/μL . Serum creatinine ≤ 1.5 x upper limit normal range , , serum creatinine &gt; 1.5 x upper limit normal range , creatinine clearance must ≥ 60 mL/min . Subjects active hepatitis B C antiviremic compound may remain treatment , except interferon . Patients history hypertension well control ( &lt; 140/90 mmHg ) regimen antihypertensive therapy . Brain metastases allow well control without seizure . Prior palliative radiation therapy bone site allow long complete two week ago . Significant cardiac disease : Congestive heart failure &gt; Class II New York Heart Association ( NYHA ) . Myocardial infarction within 6 month prior study entry . Cardiac arrhythmia require antiarrhythmic therapy beta blocker digoxin . Serious myocardial dysfunction , define scintigraphically ( MUGA , myocardial scintigram ) echocardiogram determine absolute leave ventricular ejection fraction ( LVEF ) normal ( &lt; 50 % ) . Participation concurrent investigational study . Prior locoregional therapy include drugeluting bead doxorubicin chemoembolization ( prior non drug elute bead chemoembolization doxorubicin exclude ) allow . Prior exposure systemic intravenously give doxorubicin . Pregnancy lactation . Uncontrolled intercurrent illness psychiatric illness social situation would limit compliance study requirement . Subjects history another primary cancer , exception : ) curatively resect nonmelanoma skin cancer ; b ) curatively treated cervical carcinoma situ ; c ) primary solid tumor know active disease present opinion investigator affect patient outcome set current HCC diagnosis . Allografts , include limited liver bone marrow transplant . Bleeding esophageal gastric varix within 30 day prior treatment initiation . Concomitant treatment Rifampin St John 's Wort . Patients discontinue drug least 4 week prior start protocol treatment . Subjects know HIV positive . History bleed diathesis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Liver</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>12-259</keyword>
</DOC>